• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Lower Hemoglobin Transfusion Thresholds are Safe in Hematology Oncology Patients

January 8, 2016

Human t-cell leukemia virus, artwork

Large, randomized trials have shown that restrictive versus liberal transfusions are safe for a variety of patient groups.  However, little data are available for hematology-oncology patients.  New data recently presented at the 57th American Society of Hematology Annual Meeting and Exposition suggest that lower hemoglobin thresholds may also be safe for these patients.

In a feasibility pilot trial, adult patients with acute leukemia were randomized with a 2:1 ratio for a low (7 g/dL) and high (8 g/dL) transfusion threshold, and patients were monitored for 60 days.  To date, 59 patients in the low threshold arm and 30 patients in the high threshold arm have been evaluated.  Although patients in the high threshold arm received a greater median number or red cell transfusions (p=0.01), the length of hospital stay, fatigue scores, and bleeding events were similar in both groups.  This study supports the feasibility of conducting a larger trial to confirm the safety of restrictive transfusion in acute leukemia, and perhaps, other oncologic patients.

Reference

  1. DeZern AE, Williams K, King KE, et al.  #771 Liberal Vs. Restrictive Transfusion Thresholds in Leukemia Patients:  A Feasibility Pilot Study.  American Society of Hematology 57th Annual Meeting & Exposition. Orlando, FL. December 5-8, 2015.

Filed Under

  • News
  • RBC Transfusion

Recommended

  • Low ADAMTS13 antigen and high ADAMTS13 antibody levels associated with mortality in TTP patients

  • Restrictive Transfusion Strategy for Cardiac Surgery Patients

  • Dithiothreitol (DTT)-based Method Validated for Blood Compatibility Testing in Patients Taking Daratumumab

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley